AEterna Zentaris Inc. (USA)  

(Public, NASDAQ:AEZS)   Watch this stock  
Find more results for nasdaq: aezs
1.25
0.00 (0.00%)
Jul 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.23 - 1.26
52 week 0.99 - 2.04
Open 1.25
Vol / Avg. 0.00/734,304.00
Mkt cap 70.64M
P/E     -
Div/yield     -
EPS -0.90
Shares 56.51M
Beta 1.64
Inst. own 31%
Jun 18, 2014
AEterna Zentaris Inc at Bloom Burton & Co Healthcare Investor Conference
May 9, 2014
Q1 2014 AEterna Zentaris Inc Earnings Conference Call
May 8, 2014
Q1 2014 AEterna Zentaris Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -441.13%
Operating margin - -444.96%
EBITD margin - -411.89%
Return on average assets -28.57% -42.94%
Return on average equity -103.09% -525.41%
Employees 76 -
CDP Score - -

Address

1405 du Parc-Technologique Blvd.
QUEBEC, QC G1P 4P5
Canada
+1-418-6528525 (Phone)
+1-418-9489191 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Company�s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM), as well as the further advancement of AEZS-108, for which it has completed a Phase 2 trial in advanced endometrial and advanced ovarian cancer. Its pipeline also encompasses other earlier-stage programs in oncology. AEZS-112, which is an oral anticancer agent, which includes three mechanisms of action (tubulin, topoisomerase II and angiogenesis inhibition) has completed a Phase 1 trial in advanced solid tumors and lymphoma.

Officers and directors

David A. Dodd Chairman of the Board, President, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Dennis Turpin CA Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Richard Sachse M.D., Ph.D. Senior Vice President, Chief Scientific Officer, Chief Medical Officer
Bio & Compensation  - Reuters
Jude Dinges Chief Commercial Officer, Senior Vice President
Bio & Compensation  - Reuters
Elliot Shapiro Corporate Secretary
Bio & Compensation  - Reuters
Amelie Metivier Assistant Secretary
Bio & Compensation  - Reuters
Juergen H. L. Ernst Lead Director
Age: 75
Bio & Compensation  - Reuters
M. Marcel Aubut QC Independent Director
Bio & Compensation  - Reuters
Jose P. Dorais Independent Director
Bio & Compensation  - Reuters
Carolyn Egbert Independent Director
Bio & Compensation  - Reuters